The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Virus-like particles in vaccine development
Abstract
Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
A vaccine against nicotine for smoking cessation: a randomized controlled trial
Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Bangala, Y., Guessous, I., Müller, P., Willers, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002547 · Cited by 281
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279
Heparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110
Cited by
Design of a hyperstable 60-subunit protein icosahedron
Hsia, Y., Bale, J. B., Gonen, S., Shi, D., Sheffler, W., Fong, K. K., Nattermann, U., Xu, C., Huang, P.-S., Ravichandran, R., et al. (2016) · Nature · doi:10.1038/nature18010 · Cited by 445
Abd El-Aziz, T. M., & Stockand, J. D. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104327 · Cited by 363
Bioengineering virus‐like particles as vaccines
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25159 · Cited by 355
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Metadata
- Authors
- Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2010-10
- Volume
- 9
- Issue
- 10
- Pages
- 1149-1176
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2149913957
- Cited by
- 845
- References
- 4
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virus-like particles in vaccine development. https://app.cochat.ai/papers/10.1586/erv.10.115
- The paper
- Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010). Virus-like particles in vaccine development. Expert Review of Vaccines. https://doi.org/10.1586/erv.10.115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
